{"id":"idp-118-vehicle-lotion","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site reactions"},{"rate":null,"effect":"Skin irritation"},{"rate":null,"effect":"Erythema"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IDP-118 Vehicle Lotion is a dermatological formulation that serves as a delivery system for topical agents. As a vehicle lotion, it is designed to optimize skin penetration and therapeutic efficacy of active ingredients while minimizing systemic absorption. The specific active ingredient and precise mechanism depend on the indication being studied in the Phase 3 trial.","oneSentence":"IDP-118 is a topical lotion vehicle formulation designed to deliver active pharmaceutical ingredients to the skin for localized therapeutic effect.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:15:31.165Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dermatological conditions (specific indication under Phase 3 investigation)"}]},"trialDetails":[{"nctId":"NCT05282771","phase":"EARLY_PHASE1","title":"A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2021-04-16","conditions":"Plaque Psoriasis","enrollment":402},{"nctId":"NCT02045277","phase":"PHASE2","title":"Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2014-02","conditions":"Plaque Psoriasis","enrollment":212},{"nctId":"NCT02462070","phase":"PHASE3","title":"Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2015-08-11","conditions":"Plaque Psoriasis","enrollment":203},{"nctId":"NCT02785159","phase":"PHASE2","title":"Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2016-02","conditions":"Psoriasis","enrollment":152},{"nctId":"NCT02785172","phase":"PHASE2","title":"Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2016-04","conditions":"Psoriasis","enrollment":154},{"nctId":"NCT02462122","phase":"PHASE3","title":"Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2015-08-19","conditions":"Plaque Psoriasis","enrollment":215}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vehicle","Lotion"],"phase":"phase_3","status":"active","brandName":"IDP-118 Vehicle Lotion","genericName":"IDP-118 Vehicle Lotion","companyName":"Bausch Health Americas, Inc.","companyId":"bausch-health-americas-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IDP-118 is a topical lotion vehicle formulation designed to deliver active pharmaceutical ingredients to the skin for localized therapeutic effect. Used for Dermatological conditions (specific indication under Phase 3 investigation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}